Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Collaborators (242)

Eriksson BI, Borris LC, Friedman RJ, Geerts W, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Levine M, Eriksson H, Sandrgen G, Wallin J, Bode C, Bassand JP, L├╝scher T, Angeras U, Falk A, Prins M, Leizorovicz A, Bounameaux H, Larrey D, Migge A, Beckmann H, Muehlhofer E, Caviglia H, Ceresetto J, Cicchetti A, D'Onofrio A, Diaz A, Mendler H, Saa J, Blombery P, Chong B, Gallus A, Leahy M, Salem H, Bauer N, Boehl N, Freund N, Hochreiter J, Jakubek M, Labek G, Windhager R, Zenz P, Borms T, Brabants C, Colinet J, de Rycke J, Driesen R, Gunst P, Mortele H, van Loon L, Vandermeersch E, Vanlommel D, Queiroz RD, Fridman M, Penedo JM, Schwartsmann C, Abuzgaya F, Belzile E, Dobson C, Fisher W, Grosso P, Mant M, Pototschnik R, Solymoss S, Zalzal P, Bittelman S, Cordova M, Reyes A, Rocha C, Toledo D, Altschul J, Fousek J, Koudela K, Kriz Z, Lutonsky M, Pach M, Sedivy P, Stehlik J, Svagr M, Svec M, Borgwardt OA, Joergensen P, Lassen MR, Lausten G, Mikkelsen S, Jokipii P, Pesola M, Waris P, Debue JM, Forestier C, Hennion G, Lazard T, Macaire P, Maire JY, Marouan A, Maschino X, Matuszczak Y, Moulinie JP, Osman M, Peron A, Pinson JJ, Birkner W, Buechler M, Eulert J, Fritsche HM, Guen KP, Halder A, Horacek T, Kiekenbeck A, Kleinfeld F, Krauspe R, Kurth A, Labs K, Mittelme W, Mouret P, Muehlbauer B, Quante M, Schmelz H, Wirth T, Babis G, Beldekos A, Soukakos P, Bucsi L, Lenart E, Mike G, Sarvary A, Shafiei F, Szenbeni A, Szendroi M, Toth J, Toth K, Benkovich V, Brenner B, Dekel S, Halperin N, Hendel D, Martinovich U, Nyska M, Salai M, Borghi B, Bosco M, Castelli C, Cherubino P, Franchin F, Fraschini G, Greco F, Grossi P, Gusso M, Landolfi R, Leali T, Lodigiani C, Marinoni E, Martorana U, Massari L, Melis G, Miletto A, Parise P, Rinaldi G, Riva R, Silingardi M, Porvaneckas N, Smailys A, Dijk CN, Nolte PA, Schuller HM, Slappendel R, van der List JJ, Verheyen CC, Vis HM, Aarseth O, Al-Dekany K, Borgen P, Roenning RE, Talsnes O, Bednarek A, Blacha J, Deszczyski J, Dutka J, Gazdzik T, Golec E, Gorecki A, Gusta A, Krasicki M, Kruczyski J, Kusz D, Kwiatkowsk K, Mazurkiewi S, Niedwiedzki T, Pozowski A, Skowronski J, Swaton R, Synder M, Tkaczyk T, Knapec L, Lisy M, Stasko I, Engelbrecht J, Myburgh H, van Zyl L, Canosa Sevillano R, Delgado A, Diaz Almodovar JL, Giros Torres J, Granero X, Gomar F, Lecumberri Villamedi R, Navarro Quiles A, Otero Fernandez R, Paz Jimenez J, Peidro Garces L, Pino Minguez J, Puig Verdier L, Ruiz Sanchez A, Salvador A, Valdes Casas JC, Eriksson BI, Laestander H, Liliequist J, Lind S, Paulsson B, Wykman A, Altintas F, Esemelli T, Karatosun V, Togrul E, Tozun R, Allmacher D, Buettner C, Colwell C Jr, Friedman R, Gimbel J, Jove M, King R, Martin K, Murray R, Peters P Jr, Sledge S, Swappach J, Taunton O Jr, Ward J.

Author information

  • 1Sahlgrenska University Hospital-Ostra, Gothenburg, Sweden. b.eriksson@orthop.gu.se

Abstract

BACKGROUND:

This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty.

METHODS:

In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding.

RESULTS:

A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18).

CONCLUSIONS:

A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)

2008 Massachusetts Medical Society

Comment in

PMID:
18579811
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk